The Pathophysiology of Peripheral Artery Disease

Peripheral artery disease develops through a cascade of biological events that narrows and stiffens the arteries supplying the legs, reducing blood flow to muscles and tissues downstream. The process begins with damage to the inner lining of blood vessels and escalates through inflammation, fatty plaque buildup, calcification, and eventually tissue-level injury in the muscles themselves. What makes PAD’s pathophysiology particularly interesting is that the disease is not just about a clogged pipe: the muscles, nerves, smallest blood vessels, and even the gut contribute to the damage in ways researchers are still working out.

Where It Starts: Damage to the Artery’s Inner Lining

The inner surface of every artery is covered by a single layer of endothelial cells. These cells do far more than act as a passive barrier. They regulate how much the artery relaxes or constricts, control which immune cells can enter the vessel wall, and resist the formation of blood clots. When these cells are injured or start to malfunction, the very first step toward PAD is underway.

Endothelial dysfunction sets the stage for everything that follows. The damaged lining becomes “sticky,” attracting immune cells and allowing cholesterol-laden particles to slip underneath the surface into the vessel wall. Once there, those particles trigger a slow-building inflammatory reaction that, over years, produces the fatty deposits known as plaques. A review in Frontiers in Cardiovascular Medicine describes endothelial cell dysfunction as a central contributor to PAD pathophysiology, noting that correcting it remains a largely untapped therapeutic opportunity.¹

Common risk factors attack the endothelium in overlapping ways. Smoking is one of the most potent. Cigarette smoke extracts directly injure endothelial cells, push smooth muscle cells in the artery wall into a remodeling mode, and alter the behavior of macrophages, the immune cells that consume debris inside plaques.² High blood sugar inflicts its own form of endothelial damage, which is why diabetes is such a strong driver of PAD and why the two conditions so often travel together.

Inflammation as the Engine of Plaque Growth

Once the endothelium is compromised, the immune system becomes both responder and perpetuator. Cholesterol crystals that accumulate beneath the artery lining trigger pro-inflammatory signaling molecules called cytokines. These cytokines activate the endothelium further, pulling in monocytes, lymphocytes, and neutrophils from the bloodstream.³ The result is a self-reinforcing loop: more immune cells arrive, more inflammatory signals are released, and the plaque grows.

In later stages, those same inflammatory mediators destabilize the plaque itself. They degrade the fibrous “cap” that holds the plaque together and promote cell death within the plaque’s core. When a plaque ruptures, sharp-tipped cholesterol crystals can escape into the circulation, lodging in small downstream vessels and sparking both local and body-wide inflammation that can mimic other vascular conditions.⁴ This process can also trigger blood clot formation at the rupture site, suddenly worsening the blockage.

When Artery Walls Turn to Bone

One of the more striking features of advanced PAD is vascular calcification, the literal hardening of artery walls with deposits of calcium and phosphate. This is not a passive process like mineral buildup in a water pipe. Smooth muscle cells in the artery wall undergo a transformation in which they shed their normal identity and begin behaving like bone-forming cells.⁵

Laboratory studies have shown that smooth muscle cells placed under calcifying conditions lose their characteristic markers within days and begin expressing proteins normally found in bone tissue, including osteocalcin and alkaline phosphatase.⁶ The same pattern appears in animal models whose arteries calcify spontaneously. This osteogenic switch makes the vessel rigid, reducing its ability to expand and contract with the heartbeat. Calcified lesions are among the toughest to treat with stents or balloon procedures, and they contribute to the high failure rate of interventions in the leg arteries.⁷

Blood Flow Forces and Why Location Matters

Plaques do not appear randomly along the arterial tree. They tend to develop at branch points, curves, and areas where blood flow patterns become turbulent or slow. The mechanical force that blood exerts on the vessel wall, called wall shear stress, plays a direct role. Researchers using MRI in patients with PAD found that regions of the femoral artery harboring plaques had markedly higher peak wall shear stress during systole, and the stress was distributed unevenly around the vessel’s circumference.⁸ Low shear stress in other zones promotes cholesterol accumulation and inflammation; high, uneven shear stress can destabilize existing plaques. The geometry of each person’s arteries influences where disease takes hold.

The leg arteries face an additional biomechanical challenge that arteries elsewhere do not: they bend, twist, and compress every time you walk, sit, or climb stairs. The femoropopliteal artery, which runs from the groin to behind the knee, undergoes particularly complex deformations during limb flexion.⁹ These repeated mechanical stresses help explain why stents placed in the leg arteries fracture or fail more often than those in other locations.¹⁰ Understanding the torsional forces involved is now a major focus of device engineering for PAD.

Muscle Damage Beyond the Blockage

For years, PAD was conceptualized almost entirely as a plumbing problem: blockage reduces blood supply, and everything downstream suffers proportionally. The reality is more complicated. The skeletal muscles of PAD patients develop their own internal disease, a metabolic myopathy driven by mitochondrial dysfunction and oxidative stress. Even when blood flow is partially restored, the muscles do not always recover fully because the damage has become self-sustaining within the muscle fibers themselves.¹¹

Much of this muscle-level damage comes from a pattern unique to PAD: repeated cycles of ischemia and reperfusion. When a person with PAD walks, the muscles demand more oxygen than the narrowed arteries can deliver, creating ischemia. When the person stops and rests, blood flow returns, which paradoxically generates a burst of damaging free radicals as oxygen re-enters the tissue. Over months and years, these cycles cause structural and metabolic changes in the muscle that reduce strength and function.¹² The mitochondria, the energy-producing structures inside each muscle cell, become progressively impaired. This contributes to free radical production and further inflammation, creating a vicious cycle that extends well beyond the artery blockage itself.¹³

Why Walking Hurts and What the Pain Really Means

The hallmark symptom of PAD is claudication: cramping pain in the calves, thighs, or buttocks that appears during walking and disappears with rest. The pain is not simply caused by oxygen-starved muscle tissue. Research into the nerve fibers that sense muscle pain has identified a specific receptor type, termed “N” (nociceptive), carried on unmyelinated nerve fibers that are activated only during ischemic exercise, not during normal contractions with intact blood supply.¹⁴ In other words, these pain sensors are specifically tuned to detect the metabolic environment that ischemia produces, things like low pH, elevated potassium, and accumulated metabolic waste products. That is why the pain is so reliably tied to exertion and so reliably relieved by rest.

PAD also amplifies the cardiovascular response to exercise beyond what you would expect. The blood pressure rise during walking is significantly greater in PAD patients than in healthy people, and this exaggerated response kicks in before the person even reports pain. Sympathetic nerve activity increases earlier and to a much greater degree than in matched controls at the same workload.¹⁵ The practical implication is that PAD stresses the heart and kidneys during physical activity, not just the legs. This is one reason PAD patients face elevated cardiovascular risk even beyond what the leg artery blockage alone would suggest.

The Body’s Workaround: Collateral Arteries

When a major artery becomes blocked gradually, the body has a built-in detour system. Small arterioles that already exist as connections between branches above and below the blockage begin to enlarge and remodel into functional bypass channels, a process called arteriogenesis. The trigger is mechanical: the pressure drop below the blockage creates a gradient that pushes more blood through these tiny vessels, increasing the shear stress on their walls. That stress activates the endothelium, which in turn recruits immune cells whose enzymes digest the surrounding tissue to make room for the vessel to grow.¹⁶¹⁷

This remodeling process explains why some patients with severe blockages on imaging have relatively mild symptoms: their collateral network has compensated effectively. It also explains why exercise is one of the most effective treatments for claudication. Walking forces more blood through these collateral channels, stimulating their growth. A computational modeling study found that arteriolar density in PAD patients improved by roughly a third after three months of exercise training.¹⁸ However, collateral growth has limits. It rarely restores flow completely, and in patients with critical limb ischemia, where tissue is at risk of dying, the collateral network has typically failed to keep up with demand.

Why Angiogenesis Is Not a Simple Fix

Given that PAD patients need new blood vessels, researchers have tried injecting growth factors like VEGF directly into ischemic limbs. The results have been humbling. In animal models of critical limb ischemia, overexpression of VEGF at high levels actually accelerated limb loss rather than preventing it. The new vessels that formed failed to mature properly; they lacked the smooth muscle cell coating needed for stability and function.¹⁹ The lesson is that new vessel growth requires a carefully regulated balance of growth signals, not simply more of a single factor. This is a major reason why gene therapy trials for PAD have been largely disappointing so far.

How Diabetes Amplifies the Damage

Diabetes accelerates virtually every step of PAD pathophysiology. Chronically elevated blood sugar promotes endothelial damage, increases oxidative stress, and drives a specific biochemical pathway involving compounds called advanced glycation end-products (AGEs). These are sugar-protein complexes that accumulate in vessel walls and activate a receptor called RAGE, triggering inflammation and stiffening the tissue. In a cohort of people with type 2 diabetes, higher levels of the RAGE-associated protein S100A12 were linked to an increased risk of amputation or death, and a composite RAGE-score was associated with roughly an 80 percent higher risk of those outcomes after adjusting for age and sex.²⁰ Diabetes also worsens microvascular disease, neuropathy (which masks pain signals), and wound healing, creating a particularly dangerous combination in the feet and lower legs.

Sex Differences in How PAD Develops

PAD does not behave identically in men and women. Women with PAD tend to show greater levels of inflammation, reduced ability to grow new blood vessels, and altered responses in how their arteries relax and constrict.²¹ A study of end-stage PAD patients found that while the overall plaque appearance was similar between men and women, postmenopausal women had a higher prevalence of clot material within the artery lumen and increased platelet reactivity, which could accelerate disease progression. These biological differences may arise from sex-based variation in the vascular substrate itself, meaning that men’s and women’s arteries differ in structure and in how they respond to vascular stressors even before disease begins.²² Women with PAD are also more likely to present with atypical symptoms or to be underdiagnosed, which has practical consequences for how aggressively the disease is caught and treated.

Genetics and the Susceptibility Landscape

Lifestyle and metabolic risk factors explain much of PAD, but not all of it. A genome-wide association study in the Million Veteran Program, one of the largest genetic analyses of PAD to date, identified 19 regions of the genome linked to PAD risk, 18 of which had not been reported before.²³ Many of these loci overlap with known risk genes for coronary artery disease, which makes biological sense since atherosclerosis is a systemic process. But some are unique to PAD, hinting that the leg arteries have distinct vulnerabilities. This genetic work is still in its early stages, but it reinforces that some people are biologically predisposed to develop PAD even with moderate risk factor exposure, while others with heavy exposure may be relatively protected.

The Gut Connection

An emerging line of research links PAD severity to the gut microbiome through a metabolite called trimethylamine N-oxide, or TMAO. Gut bacteria produce trimethylamine when you eat certain nutrients found in red meat, eggs, and dairy; the liver then converts it to TMAO, which promotes inflammation and plaque instability. In PAD patients, TMAO levels were substantially higher in those with critical limb ischemia compared to those with intermittent claudication. Patients with TMAO above a specific threshold had at least double the risk of cardiovascular death, even after accounting for other risk factors.²⁴ Whether lowering TMAO through dietary changes or microbiome-targeted therapies can slow PAD progression is still an open question, but the association is strong enough to have attracted serious research attention.

PAD as a Systemic Disease

One of the most consequential insights from recent research is that PAD is not just a leg problem. It is a marker of widespread atherosclerosis, and the concept of polyvascular disease, where clinically significant plaque exists in multiple arterial beds simultaneously, identifies a group of patients at especially high risk. PAD may increase the risk of heart attack, stroke, and cardiovascular death in equal or even greater magnitude than coronary artery disease or stroke alone.²⁵ This framing has shifted clinical thinking: a diagnosis of PAD now signals that the patient’s entire vascular system needs evaluation, not just the symptomatic leg. It also means that therapies targeting systemic inflammation, lipid levels, and thrombosis may matter as much for PAD patients as procedures aimed at the blockage itself.